Capecitabine-induced hypertriglyceridemia: A report of two cases

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2249-2251

  Koutras, Angelos K ^a   Habeos, Ioannis G ^a   Vagenakis, Apostolos G ^a   Kalofonos, Haralabos P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Capecitabine; Hypercholesterolemia; Hyperlipidemia; Hypertriglyceridemia

Indexed keywords

ATORVASTATIN; CAPECITABINE; CHOLESTEROL; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; NAVELBINE; OXALIPLATIN; SIMVASTATIN; TRASTUZUMAB; TRIACYLGLYCEROL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANAMNESIS; ARTICLE; BLOOD EXAMINATION; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; COLON RESECTION; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DYSLIPIDEMIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LONG TERM CARE; MALE; METASTASIS; PATHOGENESIS; PRIORITY JOURNAL; TREATMENT WITHDRAWAL;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED;

EID: 33745542022     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Diasio RB: An evolving role for oral fluoropyrimidine drugs. J Clin Oncol 20: 894-896, 2002.
2. Miwa M, Ura M, Nishida M et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281, 1998.
3. Blum JL, Jones SE, Buzdar AU et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-493, 1999.
4. O'Shaughnessy J, Miles D, Vukelja S et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823, 2002.
5. Van Cutsem E, Twelves C, Cassidy J et al: Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106, 2001.
6. Hoff PM, Ansari R, Batist G et al: Comparison of oral capecitabine (Xeloda) vs. intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282-2292, 2001.
7. Kurt M, Babaoglu MO, Yasar U et al: Capecitabine-induced severe hypertriglyceridemia: report of two cases. Ann Pharmacother 40: 328-331, 2006.
8. Stathopoulos GP, Stergiou GS, Perrea-Kostarelis DN et al: Influence of 5-fluorouracil on serum lipids. Acta Oncol 34: 253-256, 1995.
9. Gotto A and Pownall H: Manual of Lipid Disorders (third ed.). Lipinncott, Williams & Wilkins, 2003.